Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Otsuka pays up to $302mm for license to Click's CT152 for MDD

Executive Summary

Otsuka Pharmaceutical Co. Ltd. will ally with Click Therapeutics Inc. to develop and commercialize the latter's mobile software application CT152 as a prescription digital therapeutic for major depressive disorder (MDD) to treat patients either independently or in conjunction with other prescribed pharmaceuticals.
Deal Industry
  • Digital Health
  • Medical Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register